coronavirus – American Chiropractors

Hacer más ejercicio, ‘cuanto más ejercicio, mejor’, reduce el riesgo de covid-19 grave, según un estudio

adminAmericachiroES — Thu, 15 Dec 2022 11:03:28 +0000

línea superior

Hacer más ejercicio puede ayudar a reducir el riesgo de COVID-19 grave, hospitalización y muerte, según un estudio publicado el jueves en el American Journal of Preventive Medicine, que sugiere que hacer más ejercicio es mejor y se suma a la creciente investigación que subraya la barrera protectora de la actividad física. proporciona contra Covid grave.

El ejercicio protege contra los resultados graves de covid, encontraron los investigadores.

En imágenes a través de Getty Images

Hechos clave

El estudio analizó los registros de salud electrónicos de casi 200,000 pacientes adultos en Kaiser Permanente en el sur de California a quienes se les diagnosticó covid-19 entre enero de 2020 y mayo de 2021, agrupándolos en cinco categorías según los niveles de actividad, que van desde inactivos consistentemente (una actividad mediana de 0 minutos por semana) a siempre activo (una mediana de actividad de 300 minutos por semana).

Cuanto más activos eran los pacientes antes de la infección, menor era el riesgo de hospitalización o muerte dentro de los 90 días posteriores al diagnóstico de covid-19, encontraron los investigadores, y los pacientes más activos enfrentaban el menor riesgo y cada categoría inferior aumentaba las probabilidades de malos resultados. .

Los pacientes siempre inactivos tenían un 191 % más de probabilidades de ser hospitalizados y un 391 % más de probabilidades de morir que los que siempre estaban activos, encontraron los investigadores, un riesgo relativo que descendía respectivamente al 143 % y al 192 % entre los pacientes algo activos (mediana de 90 minutos de actividad por semana) y al 125% y 155% entre pacientes constantemente activos (60-150 minutos a la semana de actividad media).

El hallazgo fue consistente en todos los principales grupos demográficos, incluidos la raza, el origen étnico, el sexo y la edad, dijeron los investigadores, lo que sugiere que el ejercicio fue beneficioso a pesar de las grandes disparidades en las tasas de infección y los resultados entre los grupos demográficos.

Más ejercicio incluso se vinculó con tasas más bajas de hospitalización o muerte en pacientes con afecciones crónicas como hipertensión, obesidad y enfermedades cardiovasculares que los colocan en un mayor riesgo de enfermedades graves, dijeron los investigadores.

Efectivamente, “cuanto más ejercicio, mejor”, dijo la Dra. Deborah Rohm Young, directora de la división de investigación conductual del departamento de investigación y evaluación de Kaiser Permanente del Sur de California y autora principal del estudio.

Tangente

Si bien los investigadores encontraron beneficios de aumentar el ejercicio contra el covid para todos los grupos, encontraron que las mejoras graduales de impulsar la actividad diferían para algunos grupos. La reducción del riesgo asociada con hacer más ejercicio fue menos pronunciada entre los grupos de mayor edad y aquellos con un índice de masa corporal más alto, por ejemplo, aunque siguió siendo beneficiosa. “El mensaje principal es que cada pequeña cantidad de actividad física cuenta”, dijo Young.

Lo que no sabemos

El estudio se realizó antes de que las vacunas contra el covid-19 estuvieran ampliamente disponibles. Como resultado, los investigadores dijeron que no podían determinar si el aumento de los niveles de actividad mejoraría los resultados entre las personas vacunadas.

Antecedentes clave

El hallazgo se suma a una gran cantidad de investigaciones que demuestran los amplios beneficios para la salud del ejercicio y efectos protectores más específicos contra el covid-19. Los investigadores pidieron a los líderes de salud pública que agreguen la actividad física a la lista de estrategias de salud pública utilizadas para controlar la pandemia y alentar al público a ser más activo para protegerse. El Dr. Robert Sallis, uno de los autores principales del estudio, dijo que los hallazgos destacan vacunarse y ser más activo físicamente como “dos de las cosas más importantes que puede hacer para prevenir resultados graves de covid-19”.

Otras lecturas

Si desea vivir más tiempo, este estudio sugiere que haga mucho más ejercicio de lo recomendado anteriormente (Forbes)

El ejercicio regular reduce el riesgo de covid, sugiere un estudio (Forbes)

‘Nunca me había sentido peor’: las personas que sufren de covid durante mucho tiempo están luchando con el ejercicio (NYT)

Cobertura completa y actualizaciones en vivo sobre el Coronavirus

Sorrento organizará un webcast para discutir los datos clínicos recientemente presentados que demuestran un… | Noticias

adminAmericachiroES — Mon, 14 Nov 2022 07:01:14 +0000

ATLANTA y SAN DIEGO, 13 de noviembre de 2022 (GLOBE NEWSWIRE) — Sofusa®, una división de propiedad absoluta de Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), anunció hoy que albergará un Key Opinion Leader virtual (KOL ) mesa redonda titulada “Empoderamiento de los linfáticos: liberar el potencial de los productos biológicos que se dirigen al sistema inmunitario” que se llevará a cabo el jueves 17 de noviembre de 2022 a las 11:30 a. m. EST.

El evento contará con una inmersión profunda y una discusión sobre el diseño del estudio clínico y los datos clínicos que demuestran mejores resultados terapéuticos y funcionamiento linfático en pacientes con artritis reumatoide (AR) que reciben el tratamiento con el Sistema de administración de fármacos linfáticos Sofusa (Sofusa). Los pacientes que se inscribieron en este estudio tuvieron una respuesta inadecuada a la dosis estándar de un tratamiento subcutáneo (SC) aprobado con un inhibidor del TNF, y 10 de 10 pacientes lograron una mejora significativa en la actividad de la enfermedad y la función linfática luego del inicio del tratamiento linfático con Sofusa, con niveles de dosis a la mitad de la dosis SC anterior o menos. Estos datos fueron aceptados y presentados hoy en la reunión de Convergencia 2022 del American College of Rheumatology (ACR) en Filadelfia.

Chris Jeffers, Ph.D., JD, director ejecutivo de Mayflower BioVentures e Hibiscus BioTechnology, moderará este panel de discusión luego de la conferencia ACR. Los oradores del evento incluyen:

Roel Querubin, MD, reumatólogo certificado por la junta, Atlanta Research Center for Rheumatology y Marrieta Rheumatology Associates
Vibeke Strand, MD Profesora clínica adjunta, División de Inmunología y Reumatología, Facultad de Medicina de la Universidad de Stanford
Mike Royal, MD, director médico, Sorrento
Brian Cooley, vicepresidente sénior, jefe de desarrollo de fármacos linfáticos de Sofusa
Russell Ross, Ph.D., director técnico, desarrollo de fármacos linfáticos de Sofusa

Para registrarse para el evento en vivo, visite el sitio web de Experiencias en línea. Se puede acceder a las biografías detalladas de todos los ponentes aquí.

Después de la transmisión web en vivo, una repetición archivada estará disponible en el sitio web de la Compañía en Calendario de eventos – Sorrento Therapeutics.

Acerca de la Unidad de Negocios Sofusa de Sorrento

La Unidad de Negocios de Sofusa es una división de propiedad total de Sorrento con sede en Atlanta, Georgia, y se enfoca en el desarrollo de fármacos linfáticos con capacidades preclínicas, analíticas, de desarrollo clínico y de fabricación de dispositivos. La plataforma Sofusa es una nueva tecnología de microagujas que administra fármacos de moléculas pequeñas y grandes a través de la piel y en los capilares linfáticos iniciales, lo que da como resultado concentraciones de fármacos significativamente más altas en los ganglios linfáticos durante períodos de tiempo prolongados en comparación con las inyecciones o infusiones tradicionales. Los objetivos de fármacos para muchas enfermedades del sistema inmunitario (p. ej., enfermedades autoinmunes y cáncer) residen en el sistema linfático y los ganglios linfáticos. En múltiples modelos preclínicos, el sistema de microagujas cubierto con nanotopografía patentado de Sofusa ha demostrado consistentemente la capacidad de mejorar las respuestas terapéuticas al administrar aumentos de más de 40 veces en la concentración del fármaco a los ganglios linfáticos específicos en comparación con las inyecciones subcutáneas tradicionales o las infusiones intravenosas. Actualmente, la Unidad de Negocio de Sofusa está realizando estudios de prueba de concepto en humanos en enfermedades autoinmunes y en cáncer.

Acerca de Sorrento Therapeutics, Inc.

Sorrento es una compañía biofarmacéutica en etapa clínica y comercial que desarrolla nuevas terapias para tratar el cáncer, el dolor (tratamientos no opioides), enfermedades autoinmunes y COVID-19. El enfoque multimodal y multifacético de Sorrento para combatir el cáncer es posible gracias a sus amplias plataformas de inmunooncología, que incluyen activos clave como los inhibidores de tirosina quinasa (“TKI”) de próxima generación, anticuerpos totalmente humanos (“biblioteca G-MAB”), inmuno-celular terapias (“DAR-T”), conjugados anticuerpo-fármaco (“ADC”) y virus oncolítico (“Seprehvec”). Sorrento también está desarrollando posibles terapias antivirales y vacunas contra los coronavirus, incluidos STI-1558, Abivertinib, COVISHIELD y COVIDROPS; y soluciones de pruebas de diagnóstico, incluido COVIMARK.

El compromiso de Sorrento con las terapias que mejoran la vida de los pacientes también se demuestra con nuestro esfuerzo por promover una molécula pequeña no opioide (agonista de TRPV1) para el control del dolor, resiniferatoxina (“RTX”), y SP-102 (10 mg, gel viscoso de fosfato sódico de dexametasona ) (SEMDEXA), una novedosa formulación de gel viscoso de un corticosteroide ampliamente utilizado para inyecciones epidurales para tratar el dolor radicular lumbosacro o ciática, y para comercializar ZTlido® (sistema tópico de lidocaína) al 1,8 % para el tratamiento de la neuralgia posherpética (NPH) . RTX ha sido aprobado para un ensayo de Fase II para el dolor intratable asociado con el cáncer y un ensayo de Fase II en pacientes con osteoartritis. En marzo de 2022, se anunciaron los resultados finales positivos del Programa CLEAR del Ensayo Pivotal de Fase III para SEMDEXA, su novedoso producto no opioide para el tratamiento del dolor radicular lumbosacro (ciática). ZTlido® fue aprobado por la FDA el 28 de febrero de 2018. Para obtener más información, visite www.sorrentotherapeutics.com

Declaraciones prospectivas

Relaciones con los medios e inversores

Contacto: Brian Cooley

Correo electrónico: mediarelations@sorrentotherapeutics.com

Sorrento® y el logotipo de Sorrento son marcas registradas de Sorrento Therapeutics, Inc.

G-MAB, DAR-T, Seprehvec, SOFUSA, COVISHIELD, COVIDROPS, COVI-MSC, COVIMARK y Fujovee son marcas comerciales de Sorrento Therapeutics, Inc.

SEMDEXA (SP-102) es una marca comercial de Semnur Pharmaceuticals, Inc. Está prevista una revisión del nombre patentado por parte de la FDA.

ZTlido® es una marca comercial registrada propiedad de Scilex Pharmaceuticals Inc. Todas las demás marcas comerciales son propiedad de sus respectivos dueños.

‘Separate and unequal’: Critics say Newsom’s pricey Medicaid reforms leave most patients behind | National

adminAmericachiroES — Sun, 16 Oct 2022 12:12:52 +0000

LOS ANGELES — It wasn’t exactly an emergency, but Michael Reed, a security guard who lives in Watts, had back pain and ran out of his blood pressure medication. Unsure where else to turn, he went to his local emergency room for a refill.

Around the same time, James Woodard, a homeless man, appeared for his third visit that week. He wasn’t in medical distress. Nurses said he was likely high on meth and just looking for a place to rest.

In an overflow tent outside, Edward Green, a restaurant cook, described hearing voices and needing medication for his bipolar disorder.

The three patients were among dozens who packed the emergency room at MLK Community Hospital, a bustling health care complex in South Los Angeles reincarnated from the old hospital known as “Killer King” for its horrific patient care. The new campus serves the 1.3 million residents of Willowbrook, Compton, Watts, and other neighborhoods — a heavily Black and Latino population that suffers disproportionately high rates of devastating chronic conditions like diabetes, liver disease, and high blood pressure.

Arguably, none of the three men should have gone, on this warm April afternoon, to the emergency room, a place intended to address severe and life-threatening cases — and where care is extremely expensive.

But patients and doctors say it is nearly impossible to find a timely medical appointment or receive adequate care in the impoverished community, where fast food is easy to come by and fresh fruits and vegetables are not. Liquor stores outnumber grocery stores, and homeless encampments are overflowing. A staggering 72% of patients who receive care at the hospital rely on Medi-Cal, the state’s Medicaid program for low-income people.

“For some people, the emergency room is a last resort. But for so many people who live here, it’s literally all there is,” said Dr. Oscar Casillas, who runs the department. “Most of what I see is preventable — preventable with normal access to health care. But we don’t have that here.”

The community is short 1,400 doctors, according to Dr. Elaine Batchlor, the hospital’s CEO, who said her facility is drowning under a surge of patients who are sicker than those in surrounding communities. For instance, the death rate from diabetes is 76% higher in the community than in Los Angeles County as a whole, 77% higher for high blood pressure — an early indicator of heart disease — and 50% higher for liver disease.

But dramatic changes are afoot that could herald improvements in care — or cement the stark health disparities that persist between rich and poor communities.

Gov. Gavin Newsom is spearheading a massive experiment in Medi-Cal, pouring nearly $9 billion into a five-year initiative that targets the sickest and costliest patients and provides them with nonmedical benefits such as home-delivered meals, money for housing move-in costs, and home repairs to make living environments safer for people with asthma.

The concept — which is being tested in California on a larger scale than anywhere else in the country — is to improve patient health by funneling money into social programs and keeping patients out of costly institutions such as emergency departments, jails, nursing homes, and mental health crisis centers.

The initiative, known as CalAIM, sounds like an antidote to some of the ills that plague MLK. Yet only a sliver of its patients will receive the new and expensive benefits.

Just 108 patients — the hospital treats about 113,000 people annually — have enrolled since January. Statewide, health insurers have signed up more than 97,200 patients out of roughly 14.7 million Californians with Medi-Cal, according to state officials. And while a growing number of Medi-Cal enrollees are expected to receive the new benefits in the coming years, most will not.

Top state health officials argue that the broader Medi-Cal population will benefit from other components of CalAIM, which is a multipronged, multiyear effort to boost patients’ overall physical and mental health. But doctors, hospital leaders, and health insurance executives are skeptical that the program will fundamentally improve the quality of care for those not enrolled — including access to doctors, one of the biggest challenges for Medi-Cal patients in South Los Angeles.

“The state is now saying it will allow Medicaid dollars to be spent on things like housing and nutritious food — and those things are really important — but they’re still not willing to pay for medical care,” Batchlor said.

Batchlor has been lobbying the Newsom administration and state lawmakers to fix basic health care for the state’s poorest residents. She believes that increasing payments for doctors and hospitals that treat Medi-Cal patients could lead to improvements in both quality and access. The state and the 25 managed-care insurance plans it pays to provide health benefits to most Medi-Cal enrollees reimburse providers so little for care that it perpetuates “racism and discrimination,” she said.

Batchlor said the hospital gets about $150, on average, to treat a Medi-Cal patient in its emergency room. But it would receive about $650 if that patient had Medicare, she said, while a patient with commercial health insurance would trigger a payment of about $2,000.

The hospital brought in $344 million in revenue in 2020 and spent roughly $330 million on operations and patient care. It loses more than $30 million a year on the emergency room alone, Batchlor said.

Medicaid is generally the lowest payer in health care, and California is among the lowest-paying states in the country, experts say.

“The rates are not high enough for providers to practice. Go to Beverly Hills and those people are overdosing on health care, but here in Compton, patients are dying 10 years earlier because they can’t get health care,” Batchlor said. “That’s why I call it separate and unequal.”

Newsom in September vetoed a bill that would have boosted Medi-Cal payment rates for the hospital, saying the state can’t afford it. But Batchlor isn’t giving up. Nor are other hospitals, patient advocates, Medi-Cal health insurers, and the state’s influential doctors’ lobby, which are working to persuade Newsom and state lawmakers to pony up more money for Medi-Cal.

It’ll be a tough sell. Newsom’s top health officials defend California’s rates, saying the state has boosted pay for participating providers by offering bonus and incentive payments for improvements in health care quality and equity — even as the state adds Medi-Cal recipients to the system.

“We’ve been the most aggressive state in expanding Medi-Cal, especially with the addition of undocumented immigrants,” said Dustin Corcoran, CEO of the California Medical Association, which represents doctors and is spearheading a campaign to lobby officials. “But we have done nothing to address the patient access side to health care.”

———

The hospital previously known as Martin Luther King Jr./Drew Medical Center was forced to shut down in 2007 after a Los Angeles Times investigation revealed the county-run hospital’s “long history of harming, or even killing, those it was meant to serve.” In one well-publicized case, a homeless woman was writhing in pain and vomiting blood while janitors mopped around her. She later died.

MLK Community Hospital rose from its ashes in 2015 as a private, nonprofit safety-net hospital that runs largely on public insurance and philanthropy. Its state-of-the-art facilities include a center to treat people with diabetes and prevent their limbs from being amputated — and the hospital is trying to reach homeless patients with a new street medicine team.

Still, decades after the deadly 1965 Watts riots spurred construction of the original hospital — which was supposed to bring high-quality health care to poor neighborhoods in South Los Angeles — many disparities persist.

Less than a mile from the hospital, 60-year-old Sonny Hawthorne rattled through some trash cans on the sidewalk. He was raised in Watts and has been homeless for most of his adult life, other than stints in jail for burglary.

He hustles on his bike doing odd jobs for cash, such as cleaning yards and recycling, but said he has trouble filling out job applications because he can’t read. Most of his day is spent just surviving, searching for food and shelter.

Hawthorne is one of California’s estimated 173,800 homeless residents, most of whom are enrolled in Medi-Cal or qualify for the program. He has diabetes and high blood pressure. He had been on psychotropic medicine for depression and paranoia but hasn’t taken it in months or years. He can’t remember.

“They wanted me to come back in two weeks, but I didn’t go,” he said of an emergency room visit this year for chronic foot pain associated with diabetes. “It’s too much responsibility sometimes.”

Hawthorne’s chronic health conditions and homelessness should qualify him for the CalAIM initiative, which would give him access to a case manager to help him find a primary care doctor, address untreated medical conditions, and navigate the new social services that may be available to him under the program.

But it’s not up to him whether he receives the new benefits.

The state has yielded tremendous power to Medi-Cal’s managed-care insurance companies to decide which social services they will offer. They also decide which of their sickest and most vulnerable enrollees get them.

One benefit all plans must offer is intensive care management, in which certain patients are assigned to case managers who help them navigate their health and social service needs, get to appointments, take their medications regularly, and eat healthy foods.

Plans can also provide benefits from among 14 broad categories of social services, such as six months of free housing for some homeless patients discharged from the hospital, beds in sobering centers that allow patients to recover and get clean outside the emergency room, and assistance with daily tasks such as grocery shopping.

L.A. Care Health Plan, the largest Medi-Cal managed-care insurer in Los Angeles County, with more than 2.5 million enrollees, is contracting with the hospital, which will provide housing and case management services under the initiative. For now, the hospital is targeting patients who are homeless and repeat emergency room visitors, said Fernando Lopez Rico, who helps homeless patients get services.

So far, the hospital has referred 78 patients to case managers and enrolled 30 other patients in housing programs. Only one has been placed in permanent housing, and about 17 have received help getting temporary shelter.

“It is very difficult to place people,” Lopez Rico said. “There’s almost nothing available, and we get a lot of hesitancy and pushback from private property owners not wanting to let these individuals or families live there.”

Patrick Alvarez, 57, has diabetes and was living in a shed without running water until July, when an infection in his feet grew so bad that he had several toes amputated.

The hospital sent him to a rehabilitation and recovery center, where he is learning to walk again, receiving counseling, and looking for permanent housing.

If he finds a place he can afford, CalAIM will pay his first month’s and last month’s rent, the security deposit, and perhaps even utility hookup fees.

But the hunt for housing, even with the help of new benefits, is arduous. A one-bedroom apartment he saw in September was going for $1,600 a month and required a deposit of $1,600. “It’s horrible, I can’t afford that,” he said.

Hawthorne needs help just as badly. But he’s unlikely to get it since he doesn’t have a phone or permanent address — and wouldn’t be easy for the hospital to find. The homeless encampments where he lives are routinely cleared by law enforcement officials.

“We have so many more people who need help than are able to get it,” Lopez Rico said. “There aren’t enough resources to help everyone, so only some people get in.”

———

L.A. Care has referred about 28,400 members to CalAIM case managers, roughly 1% of its total enrollees, according to its CEO, John Baackes. It is offering housing, food, and other social services to even fewer: about 12,600 people.

CalAIM has the potential to dramatically improve the health of patients who are lucky enough to receive new benefits, Baackes said. But he isn’t convinced it will save the health care system money and believes it will leave behind millions of other patients — without greater investment in the broader Medi-Cal program.

“Access is not as good for Medi-Cal patients as it is for people with means, and that is a fundamental problem that has not changed with CalAIM,” Baackes said.

Evidence shows that basic Medi-Cal patient care is often subpar.

Year-over-year analyses published by the state Department of Health Care Services, which administers Medi-Cal, have found that, by some measures, Medi-Cal health plans are getting worse at caring for patients, not better. Among the most recent findings: The rates of breast and cervical cancer screenings for women were worse in 2020 than 2019, even when the demands that COVID-19 placed on the health care system were factored into the analysis. Hospital readmissions increased, and diabetes care declined.

“The impact of COVID is real — providers shut down — but we also know we need a lot of improvement in access and quality,” said State Medicaid Director Jacey Cooper. “We don’t feel we are where we should be in California.”

Cooper said her agency is cracking down on Medi-Cal insurance plans that are failing to provide adequate care and is strengthening oversight and enforcement of insurers, which are required by state law to provide timely access to care and enough network doctors to serve all their members.

The state is also requiring participating health plans to sign new contracts with stricter quality-of-care measures.

Cooper argues CalAIM will improve the quality of care for all Medi-Cal patients, describing aspects of the initiative that require health plans to hook patients up with primary care doctors, connect them with specialty care, and develop detailed plans to keep them out of expensive treatment zones like the emergency room.

She denied that CalAIM will leave millions of Medi-Cal patients behind and said the state has increased incentive and bonus payments so health care providers will focus on improving care while implementing the initiative.

“CalAIM targets people who are homeless and extremely high-need, but we’re also focusing on wellness and prevention,” she told KHN. “It really is a wholesale reform of the entire Medicaid system in California.”

A chorus of doctors, hospital leaders, health insurance executives, and health care advocates point to Medi-Cal reimbursement rates as the core of the problem. “The chronic condition in Medi-Cal is underfunding,” said Linnea Koopmans, CEO of the Local Health Plans of California.

Although the state has restored some previous Medi-Cal rate cuts, there’s no move to increase base payments for doctors and hospitals. Cooper said the state is using tobacco tax dollars and other state money to attract more providers to the system and to entice doctors who already participate to accept more Medi-Cal patients.

When Newsom vetoed the bill to provide higher reimbursements primarily for emergency room care at MLK, he said the state cannot afford the “ tens of millions ” of dollars it would cost.

MLK leaders vow to continue pushing, while other hospitals and the powerful California Medical Association plot a larger campaign to draw attention to the low payment rates.

“Californians who rely on Medi-Cal — two-thirds of whom are people of color — have a harder time finding providers who are willing to care for them,” said Jan Emerson-Shea, a spokesperson for the California Hospital Association.

For Dr. Oscar Casillas at MLK, the issue is critical. Although he’s a highly trained emergency physician, most days he practices routine primary care, addressing fevers, chronic foot and back pain, and missed medications.

“If you put yourself in the shoes of our patients, what would you do?” asked Casillas, who previously worked as an ER doctor in the affluent coastal city of Santa Monica. “There’s no reasonable access if you’re on Medi-Cal. Most of the providers are by the beach, so emergency departments like ours are left holding the bag.”

———

(KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation. This story is part of a partnership that includes WLRN, NPR and KHN.)

Sorrento informa resultados positivos de ensayos que utilizan la administración linfática de etanercept de Sofusa,… | Noticias

adminAmericachiroES — Thu, 15 Sep 2022 17:29:25 +0000

Sorrento ha completado su primer estudio de prueba de concepto en humanos de Fase 1b en el que los primeros 7 de 7 pacientes con una respuesta inicial inadecuada a las inyecciones subcutáneas de etanercept lograron mejoras significativas en la actividad de la enfermedad cuando cambiaron a la administración linfática de Sofusa.
Los resultados se presentarán en la Conferencia de Convergencia 2022 del Colegio Estadounidense de Reumatología (ACR) el 13 de noviembre de 2022 como un resumen y un póster titulado “La administración linfática de etanercept logra mejoras significativas en las medidas de la enfermedad de artritis reumatoide al 50 % de la dosis estándar para pacientes con una respuesta inadecuada a las inyecciones subcutáneas”.

SAN DIEGO, 15 de septiembre de 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) anunció hoy la finalización de su primer estudio de prueba de concepto de fase 1b utilizando el sistema de administración de fármacos linfáticos Sofusa (Sofusa) .

STI-SOFUSA-1003 es un estudio de prueba de concepto de Fase 1b diseñado para evaluar la seguridad y también probar la hipótesis de que el perfil de biodistribución único de Sofusa podría mejorar la respuesta clínica, reducir la cantidad de fármaco necesaria para lograr una respuesta, o ambas cosas. Para ser elegible para el estudio, los participantes debían estar en una dosis estable de 50 mg de etanercept y no responder adecuadamente al tratamiento subcutáneo con etanercept.

Los resultados preliminares indican que el 100 % de los pacientes (7 de 7) que completaron la primera cohorte del estudio (12 semanas) lograron una mejora significativa en su actividad de la artritis reumatoide al 50 % de la dosis subcutánea (25 mg). El Comité de selección de resúmenes de ACR ha aceptado un resumen titulado “La administración linfática de etanercept logra mejoras significativas en las medidas de la enfermedad de artritis reumatoide al 50 % de la dosis estándar para pacientes con una respuesta inadecuada a las inyecciones subcutáneas”, disponible en https://acrabstracts.org /resumen/la-administración-linfática-de-etanercept-logra-mejoras-significativas-en-la-artritis-reumatoide-enfermedad-medida-a-50-de-la-dosis-estándar-para-pacientes-con-una-respuesta-inadecuada -a-inyección-subcutánea/

Los resultados completos del estudio de prueba de concepto de la Fase 1b se presentarán en la Conferencia ACR Convergence 2022 el 13 de noviembre de 2022 por Russell Ross, Ph.D., Director Técnico de la Unidad de Negocios Sofusa de Sorrento. “Estamos muy animados por estos resultados y agradecidos por la aceptación de nuestra publicación por parte de la ACR. La plataforma Sofusa está cumpliendo la promesa que esperábamos cuando adquirimos esta plataforma. La tecnología, combinada con nuestra biblioteca G-MAB patentada y las capacidades de fabricación de anticuerpos, nos brinda un motor para desarrollar una línea de terapias linfáticas novedosas para enfermedades autoinmunes, cánceres y enfermedades infecciosas”, afirmó Henry Ji, Ph.D., presidente y CEO de Sorrento. “Esto también da esperanza a los muchos pacientes que no logran una respuesta adecuada a las terapias biológicas actuales administradas mediante inyecciones e infusiones tradicionales”, continuó.

Acerca de la Unidad de Negocios Sofusa de Sorrento

La Unidad de Negocios de Sofusa es una división de propiedad total de Sorrento con sede en Atlanta, Georgia, y se enfoca en el desarrollo de fármacos linfáticos con capacidades preclínicas, analíticas, de desarrollo clínico y de fabricación de dispositivos. La plataforma Sofusa es una nueva tecnología de microagujas que administra fármacos de moléculas pequeñas y grandes a través de la piel y en los capilares linfáticos, lo que da como resultado concentraciones de fármacos significativamente más altas para los objetivos de los fármacos del sistema inmunitario durante períodos de tiempo más prolongados que las inyecciones o infusiones tradicionales. Los objetivos de fármacos para muchas enfermedades del sistema inmunitario (p. ej., enfermedades autoinmunes y cáncer) residen en el sistema linfático y los ganglios linfáticos. En múltiples modelos preclínicos, el sistema de microagujas cubierto con nanotopografía patentado de Sofusa ha demostrado consistentemente la capacidad de mejorar las respuestas terapéuticas al administrar aumentos de más de 40 veces en la concentración del fármaco a los ganglios linfáticos específicos en comparación con las inyecciones subcutáneas tradicionales o las infusiones intravenosas. Actualmente, la Unidad de Negocio de Sofusa está realizando estudios de prueba de concepto en humanos en enfermedades autoinmunes y en cáncer.

Acerca de Sorrento Therapeutics, Inc.

Sorrento es una compañía biofarmacéutica en etapa clínica y comercial que desarrolla nuevas terapias para tratar el cáncer, el dolor (tratamientos no opioides), enfermedades autoinmunes y COVID-19. El enfoque multimodal y multifacético de Sorrento para combatir el cáncer es posible gracias a sus amplias plataformas de inmunooncología, que incluyen activos clave como los inhibidores de tirosina quinasa (“TKI”) de próxima generación, anticuerpos totalmente humanos (“biblioteca G-MAB”), inmuno -terapias celulares (“DAR-T”), conjugados anticuerpo-fármaco (“ADC”) y virus oncolíticos (“Seprehvec”). Sorrento también está desarrollando posibles terapias antivirales y vacunas contra los coronavirus, incluidas STI-1558, COVISHIELD y COVIDROPS; y soluciones de pruebas de diagnóstico, incluido COVIMARK.

Para obtener más información, visite www.sorrentotherapeutics.com

Declaraciones prospectivas

Este comunicado de prensa y cualquier declaración realizada para y durante cualquier presentación o reunión contienen declaraciones a futuro relacionadas con Sorrento Therapeutics, Inc., bajo las disposiciones de puerto seguro de la Sección 21E de la Ley de Reforma de Litigios de Valores Privados de 1995 y sujetas a riesgos e incertidumbres. que podría causar que los resultados reales difieran materialmente de los proyectados. Las declaraciones prospectivas incluyen declaraciones sobre el sistema de administración de fármacos linfáticos de Sofusa, incluidos los resultados preliminares del estudio de prueba de concepto de fase 1b; la capacidad potencial del Sistema Linfático de Administración de Fármacos Sofusa para mejorar la respuesta clínica, reducir la cantidad de fármaco necesaria para lograr una respuesta, o ambas cosas; y la capacidad de Sorrento para desarrollar una línea de nuevas terapias linfáticas para enfermedades autoinmunes, cánceres y enfermedades infecciosas. Los riesgos e incertidumbres que podrían causar que nuestros resultados reales difieran material y negativamente de los expresados en nuestras declaraciones prospectivas incluyen, entre otros: riesgos relacionados con las tecnologías y perspectivas de Sorrento, incluidos, entre otros, riesgos relacionados con la seguridad y la eficacia del sistema de administración de fármacos linfáticos Sofusa y la búsqueda de la aprobación reglamentaria para el sistema de administración de fármacos linfáticos Sofusa; riesgos de desarrollo clínico, incluidos los riesgos en el progreso, el tiempo, el costo y los resultados de los ensayos clínicos y los programas de desarrollo de productos; riesgo de dificultades o retrasos en la obtención de aprobaciones regulatorias; los riesgos de que los resultados de los estudios clínicos no cumplan con alguno o todos los criterios de valoración de un estudio clínico y que los datos generados a partir de dichos estudios no respalden una presentación o aprobación reglamentaria; riesgos de que los resultados de pruebas, estudios y ensayos anteriores no se reproduzcan en estudios y ensayos continuos o futuros; riesgos de fabricación y suministro de productos farmacéuticos; riesgos relacionados con el aprovechamiento de la experiencia de sus empleados, subsidiarias, afiliados y socios para ayudar a Sorrento en la ejecución de las estrategias de sus productos candidatos; riesgos relacionados con el impacto global de COVID-19; y otros riesgos que se describen en los informes periódicos más recientes de Sorrento presentados ante la Comisión de Bolsa y Valores, incluido el Informe anual de Sorrento en el Formulario 10-K para el año finalizado el 31 de diciembre de 2021 y los Informes trimestrales posteriores en el Formulario 10-Q presentado ante la Securities y Exchange Commission, incluidos los factores de riesgo establecidos en dichas presentaciones. Se advierte a los inversores que no confíen indebidamente en estas declaraciones prospectivas, que se refieren solo a la fecha de este comunicado, y no asumimos ninguna obligación de actualizar ninguna declaración prospectiva en este comunicado de prensa, excepto según lo exija la ley.

Relaciones con los medios e inversores

Contacto: Brian Cooley

Correo electrónico: mediarelations@sorrentotherapeutics.com

Sorrento® y el logotipo de Sorrento son marcas registradas de Sorrento Therapeutics, Inc.

G-MAB, DAR-T, Seprehvec, SOFUSA, COVISHIELD, COVIDROPS, COVI-MSC, COVIMARK y Fujovee son marcas comerciales de Sorrento Therapeutics, Inc.

SEMDEXA (SP-102) es una marca comercial de Semnur Pharmaceuticals, Inc. Está prevista una revisión del nombre patentado por parte de la FDA.

ZTlido® es una marca registrada propiedad de Scilex Pharmaceuticals Inc.

Todas las demás marcas comerciales son propiedad de sus respectivos dueños.

Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement … | News

adminAmericachiroES — Wed, 17 Aug 2022 15:57:34 +0000

PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Distribution Agreement (“Agreement”) for certain designated territories with CH Trading Group LLC (“CH Trading”), an international import, export and trading company focused on the Middle East and North Africa (MENA) Region and other markets, to distribute Scilex’s lead non-opioid commercial pain management product, ZTlido®. Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”).

“Our Agreement with CH Trading is another significant step in our continuing efforts to expand our global presence with our portfolio of innovative non-opioid pain management products, to address unmet medical needs. We are extremely pleased to collaborate with CH Trading, whose deep expertise and relationships will help us build a solid foundation in key MENA Region and other markets,” said Henry Ji, Ph.D., Executive Chairman of Scilex and Chairman and Chief Executive Officer of Sorrento.

“We are pleased to work with CH Trading to help support us through the processes of obtaining global Halal certification as well as regulatory approval in the overseas designated territories, so that we may continue to fulfill our mission to address patient pain management needs with ZTlido®,” said Jaisim Shah, Chief Executive Officer of Scilex.

“We are delighted to work with a non-opioid pain management leader like Scilex for distribution of ZTlido® into these markets,” said Elsayed Zayan, CEO of the CH Group family of companies, which include CH Trading. “Our mission is to promote healthy, ethical and productive lifestyle, including bringing innovative products to people throughout the OIC countries and the GCC and MENA Regions. Aligning with Scilex’s global ambitions means that together we can help more patients, partners, and public health systems collectively benefit.”

Scilex Holding Company and Vickers Vantage Corp. I (Nasdaq: VCKA) (“Vickers”), a special purpose acquisition company sponsored by Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, have entered into a definitive business combination agreement (“BCA”) on March 17, 2022. Upon the closing of the transaction, the combined company (the “Combined Company”) will be renamed Scilex Holding Company, and its common stock and warrants to purchase common stock are expected to be listed on Nasdaq under the ticker symbol “SCLX” and “SCLXW,” respectively. The boards of directors of each of Vickers, Scilex and Sorrento have unanimously approved the proposed transaction. The closing of the transaction, which is expected to occur by the third quarter of 2022, is subject to the approval of Vickers’s shareholders and the satisfaction or waiver of certain other customary closing conditions.

About CH Trading Group

CH Trading Group LLC (“CH Trading”) is part of the CH Group family of companies ( www.chgroupus.com ). CH Group constitutes a diversified conglomerate targeting eight economic “Sectors”: healthcare, pharmaceuticals, food, finance, cosmetics, tourism, fashion, media/entertainment. Spanning a variety of multi-national products, services and solutions, its world mission involves connecting, developing and promoting, from Local to Global and throughout the world, all aspects of a wholesome, healthy and productive lifestyle.

CH Trading focuses on international import/export and trade, prioritizing the countries of the Organization of Islamic Cooperation (OIC) and Middle East North Africa (MENA) and Gulf Cooperation Council (GCC) Regions. It has responded to worldwide demands for identifying and securing supply chains by introducing innovative products, including from the US, and developing a robust distribution network for goods.

About Scilex Holding Company

Scilex Holding Company, a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercialization of non-opioid pain management products for treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain. Scilex launched its first commercial product in October 2018, in-licensed a commercial product in June 2022, and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate and one Phase 2 and one Phase 1 candidate. Its commercial product, ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. Scilex in-licensed the exclusive right to commercialize Gloperba® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex is planning to commercialize Gloperba® beginning in the first half of 2023 and is well-positioned to market and distribute the product. Scilex’s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2, triple-strength formulation of ZTlido®, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 programs expected to be initiated this year. For further information regarding the SP-102 Phase 3 efficacy trial, see NCT identifier NCT03372161 – Corticosteroid Lumbar Epidural Analgesia for Radiculopathy – Full Text View – ClinicalTrials.gov.

Scilex Holding Company is headquartered in Palo Alto, California, with operations in both Palo Alto and San Diego, California. For further information please visit www.scilexholding.com.

About Sorrento Therapeutics

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB library”), immuno-cellular therapies (“DAR-T”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVISHIELD and COVI-MSC; and diagnostic test solutions, including COVIMARK.

Sorrento’s commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com

About Vickers Vantage Corp. I

Vickers Vantage Corp. I is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

Important Information for Investors and Stockholders

This press release relates to a proposed transaction between Scilex and Vickers. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the transaction described herein, Vickers has filed a Registration Statement on Form S-4 (the “Registration Statement”), which includes a document that serves as a prospectus and proxy statement of Vickers, referred to as the proxy statement/prospectus. After the Registration Statement is declared effective by the SEC, the proxy statement/prospectus will be sent to all Vickers shareholders as of a record date for the meeting of Vickers shareholders to be established for voting on the proposed business combination. Vickers will also file other documents regarding the proposed transaction with the SEC. This press release does not contain all of the information that will be contained in the proxy statement/prospectus or other documents filed or to be filed with the SEC. Investors and security holders of Vickers are urged to read these materials (including any amendments or supplements thereto) and any other relevant documents in connection with the transaction that Vickers files with the SEC when, and if, they become available because they will contain important information about Vickers, Scilex and the proposed transaction. Investors and security holders will be able to obtain free copies of the Registration Statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Vickers through the website maintained by the SEC at www.sec.gov.

Participants in the Solicitation

Vickers and its directors and executive officers may be deemed participants in the solicitation of proxies from Vickers’s shareholders in connection with the transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be contained in the proxy statement/prospectus when available. You may obtain free copies of these documents as described in the preceding paragraph.

Scilex and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Vickers in connection with the proposed transaction. Information about Scilex’s directors and executive officers and information regarding their interests in the proposed transaction will be included in the proxy statement/prospectus for the proposed transaction.

Non-Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Vickers, the Combined Company or Scilex, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Vickers, Sorrento and its subsidiaries, including but not limited to Scilex, under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the impact of CH Group’s expertise in helping expand the commercialization of ZTlido® in key Middle East and North Africa markets, the proposed business combination between Scilex and Vickers, including the timing of such business combination, the potential listing of the Combined Company’s common stock and warrants to purchase common stock on Nasdaq or other major securities exchange and the anticipated stock ticker symbol for such shares and warrants to purchase common stock, the expectation that Vickers will file subsequent amendments to the Registration Statement on Form S-4, the estimated or anticipated future results and benefits of the Combined Company following the proposed business combination, including the likelihood and ability of the parties to successfully consummate the proposed business combination, future opportunities for the Combined Company, the timing of the completion of the proposed business combination, Scilex’s and the Combined Company’s proposed business strategies, the expected cash resources of the Combined Company and the expected uses thereof; Scilex’s and the Combined Company’s current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity; statements regarding SP-102 (SEMDEXA), SP-103 or SP-104, if approved by the FDA; Scilex’s development and commercialization plans; and Sorrento’s products, technologies and prospects and Scilex’s products, technologies and prospects. Risks and uncertainties that could cause Sorrento’s and Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: the inability of the parties to consummate the proposed business combination transaction for any reason or the occurrence of any event, change or other circumstances that could give rise to the termination of the BCA, including any failure to meet applicable closing conditions; changes in the structure, timing and completion of the proposed transaction between Vickers and Scilex; Vickers’s ability to continue its listing on the Nasdaq Capital Market until closing of the proposed transaction; the Combined Company’s ability to list its securities on Nasdaq or other major securities exchange after closing of the proposed transaction; the ability of the parties to achieve the benefits of the proposed transaction, including future financial and operating results of the Combined Company; the ability of the parties to realize the expected synergies from the proposed transaction; risks related to the outcome of any legal proceedings that may be instituted against the parties following the announcement of the proposed business combination; general economic, political and business conditions; risks related to the ongoing COVID-19 pandemic; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the results of the Phase 2 trial for SP-103 or Phase 1 trials for SP-104 may not be successful; risks that the prior results of the clinical trials of SP-102 (SEMDEXA), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; the risk that any requisite regulatory approvals to complete the transaction are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the Combined Company or the expected benefits of the proposed transaction or that the approval of Vickers’s shareholders is not obtained; the risk of failure to realize the anticipated benefits of the proposed transaction; the amount of redemption requests made by Vickers’s shareholders and other risks and uncertainties indicated from time to time and other risks set forth in Sorrento’s and Vickers’s filings with the SEC, including in the Registration Statement. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as may be required by law.

Contacts:

For Scilex Holding Company

Jaisim Shah

Chief Executive Officer

Scilex Holding Company

960 San Antonio Road

Palo Alto, CA 94303

Office: (650) 516-4310

Email: jshah@scilexpharma.com

Website: www.sorrentotherapeutics.com and www.scilexholding.com

Investors and Media Contact:

Contact:

Brian Cooley

Email: mediarelations@sorrentotherapeutics.com

Website: www.sorrentotherapeutics.com

For Vickers Vantage Corp. I

Jeffrey Chi

Chief Executive Officer

85 Broad Street, 16th Floor

New York, NY 10004

Phone: (646) 974-8301

Email: jeff.chi@vickersventure.com

Website: www.vickersvantage.com

Investors and Media Contact: Nicolette Ten, Senior Account Executive, SPRG

Email: nicolette.ten@sprg.com.sg

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB, DAR-T, Seprehvec, SOFUSA, COVISHIELD, COVI-MSC, and COVIMARK are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly owned subsidiary of Scilex Holding Company.

Gloperba® is an exclusive, transferable license to use the trademark by Scilex Holding Company.

All other trademarks are the property of their respective owners.